TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Major Pathologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of CJ-12420
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival rates of the implants
Endpoint domain: Mortality/survival
Primary endpoint: rate of successful IUD insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Sleep satisfaction score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Histological diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response to prophylactic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Subjects With Myocardial Scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time Required for 50% of Radioactivity to be Emptied from the Stomach
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Borderline Symptom Checklist (BSL-23)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: patient - graft survival
Endpoint domain: Mortality/survival
Primary endpoint: Medication discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients that are satisfied with treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in depression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in tumor uptake of [18F]- ML-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: HBV DNA titer <20,000 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologic evaluation of treated skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number and percentage of Participants with Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Radiological antitumor activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Elderly Health Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Growth measured by weight for age and height
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence/metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Changes in Gingival crevicular fluid (GCF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prominence of motor blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of Patients With Successful Preparations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence rate of progression from stage 1 ROP to zone II stage 2 ROP with plus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Incidence rate of progression from stage 1 ROP to zone II stage 3 ROP with plus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Disease Progression as Assessed by the ALSFRS-R Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality Event Rate
Endpoint domain: Mortality/survival
Primary endpoint: HIV viral load in CSF and plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypothetical trial enrollment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of WHO grade 3 or 4 oral mucositis
Endpoint domain: Adverse events/effects
Primary endpoint: Characterization of hepatitis disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mp microfilaremia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early Insulin Exposure (%AUC[0-60])
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Cormack-Lehane Grade >2 Obtained With CMAC D Blade
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Participants With Cormack-Lehane Grade >2 Obtained With Glidescope AVL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in lymphocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in total white blood cell (WBC) count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Participants' level of distress in the month preceding the measurement as assessed with the total Score of the Perceived Stress Scale 14 (PSS-14)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of comorbidities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of virologic failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Health Behaviors
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Resiliency
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Well-Being
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Extensive Radiographic Osteonecrosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Participants With Infusion-Associated Reactions (IARs)
Endpoint domain: Adverse events/effects
Primary endpoint: Doppler Echocardiogram: Absolute Change From Baseline in Left Ventricular Ejection Fraction at Week 52
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glucose Sensor Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Knee injury and Osteoarthritis Outcome Score (KOOS) total
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: International Knee Documentation Committee Subjective Knee Evaluation Form (IKDC) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: number of surgical interventions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in number of weekly notified dengue cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in the duration of dengue outbreaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: BV/TV bone volume fraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the concentration-time curve of ethinylestradiol and levonogestrel in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum measured concentration of ethinylestradiol and levonogestrel in plasma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the level of Heparin-binding protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to administer first analgesic bolus of morphine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Study completion rate
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Time to Steady State
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CST½
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Distinctive curves of glucose and hormones during mixed meal tolerance test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Patients with Response to Antibiotic Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: scores on depression scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: scores on substance use scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: scores on functioning scales
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: reduction in total laser time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: reduction in total OR time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in 24-hour ambulatory systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immune Response to Vaccinations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Voice Handicap Index Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of food allergies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Cervical Cancer Screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Pittsburgh Sleep Quality Index (PSQI) score
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Percentage Reduction in Total Seizure Frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants Reporting Local and Systemic Solicited Reactogenicity Events Post First Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Reporting Serious and Non-serious Adverse Events (AE) Through Day 29
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean Titers (GMTs) of Serum Hemagglutination Inhibition (HAI) Against the 2018/2019 Quadrivalent Influenza Vaccine (QIV) Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Survival in patients with ALS
Endpoint domain: Mortality/survival
Primary endpoint: Metabolic signature of muscle, mRNA gene expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC for Symptom Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who respond to treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients who are able to progress to potentially curative treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: LIF Protein Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: change from baseline in mean CIMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in refractive error in myopia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax of linzagolix and KP017
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tmax of linzagolix and KP017
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-t of linzagolix and KP017
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: T1/2 of linzagolix and KP017
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of mature follicle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Time to Incident Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Magnitude of induced nocebo hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in alanine-aminotransferase (ALAT) activity in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: recurrent obstruction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: decrease renal function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Freedom From Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Spillage of intracystic content rate
Endpoint domain: Adverse events/effects
Primary endpoint: Chemical peritonitis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Immunization status (DPT3 completed vs not completed)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: BMI at one year after randomization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apposition and neointimal coverage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Translocator total distribution volume (TSPO VT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective Remission Rate (ORR) in Relapsed or Refractory AML
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Objective Remission Rate (ORR) in Newly Diagnosed AML
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cumulative Number of New Active Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: POSAS Patient Scale Total Sum of Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in MDS-UPDRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in measure of platelet aggregometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in measure of Endothelial Function Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in blood pressure measured with an automated blood pressure instrument
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in the number of total cells in bronchoalveolar lavage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of subjects receiving liver resection/liver transplantation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quantification of residual opioids
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Orthostatic weight exceeding 1.4 kg/day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to CMV infection
Endpoint domain: Adverse events/effects
Primary endpoint: AE of local and systemic reactions within 30 minutes after each dose
Endpoint domain: Adverse events/effects
Primary endpoint: All active AEs within 0-7 days after each dose
Endpoint domain: Adverse events/effects
Primary endpoint: All SAEs within 6 months after the last dose is vaccinated
Endpoint domain: Adverse events/effects
Primary endpoint: Measure of Disruptive Behavior Disorder (DBD) Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Measure of Child's Impairment
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in behavior measured by the IOWA Conners Oppositional/Defiant Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leakage of autologous blood through bronchial cuff
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acute Respiratory Infection (ARI) Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cleft size measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain uptake of radioligand
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Number of Participants With Treatment Escalations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to Treatment Escalation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in soluble intercellular adhesion molecule (ICAM) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Presence of CB1 receptor protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of CB2 receptor protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of cannabinoid receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Angiomyolipomata
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 7-point plasma glucose profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Hospitalization Events
Endpoint domain: Adverse events/effects
Primary endpoint: Prevalence of circulating parvovirus genome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: renal function change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: renal blood flow change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Peak oxygen uptake (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Six Minute Walk Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of serum concentration of pCS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Photographic Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimated Cigarettes Taken at Free Price
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in Blood Nicotine Content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood nutritional status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Myometric measures of strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Manual muscle testing (MRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Graded Redefined Assessment of Strength, Sensibility and Prehension test (GRASSP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Difference in Visual Analogue Scale (VAS) for ocular discomfort
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Histologically controlled complete clearance of actinic keratosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Mean Change in Frequency of Moderate to Severe VMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change in Hot Flash Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with modes of delivery
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Mean Rate of Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in systolic blood pressure (SBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from Baseline in diastolic blood pressure (DBP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: AOFAS score at 6 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AOFAS score at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long term complications of disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TPTD measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GEDV measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EVLW measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Achieving Complete or Partial Response 4 Months After Completion of Study Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with negative urea breath test post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of downstaging to pathological complete response or ypT1 disease with negative margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aortic root diameter (sinuses of Valsalva)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Glucolipid metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pressure hyperalgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change of Proteinuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in cost-effectiveness data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in cost-utility data
Endpoint domain: Resource use
Endpoint subdomain: Other resource use